Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
Pfizer's Phase 2 study of ponsegromab met primary endpoint, showing significant body weight increases compared to placebo across all doses, with a 5.61% mean increase at the highest dose after 12 weeks. Ponsegromab was generally safe and well-tolerated, with improvements in appetite, cachexia symptoms, physical activity, and muscle mass at the highest dose. Pfizer plans to initiate registration-enabling studies in 2025.
Related Clinical Trials
Reference News
Researchers found a drug, ponsegromab, effectively treats cachexia in cancer patients by blocking the GDF-15 hormone, improving symptoms with minimal side effects, as reported in a phase 2 clinical trial in the New England Journal of Medicine.
Pfizer's Phase 2 study of ponsegromab, targeting GDF-15 in cancer cachexia, showed significant weight gain and improvements in muscle mass, quality of life, and physical function. Positive results pave way for registration-enabling studies in 2025. Additionally, Pfizer's RSV vaccine, ABRYSVO, showed potential to protect high-risk adults from RSV in a Phase 3 trial.
Pfizer's experimental drug ponsegromab, targeting cancer-related cachexia, shows promising results in phase 2 clinical tests, potentially improving weight, muscle mass, and quality of life for patients.
Pfizer's Phase 2 study of ponsegromab met its primary endpoint, showing a 5.6% mean increase in body weight at the highest dose compared to placebo in cancer cachexia patients. Ponsegromab was safe and well-tolerated, with improvements in appetite, cachexia symptoms, physical activity, and muscle mass. Registration-enabling studies are planned for 2025.
Researchers found ponsegromab, a drug blocking GDF-15 hormone, effectively treats cachexia in cancer patients, improving symptoms with minimal side effects, according to a phase 2 clinical trial published in the New England Journal of Medicine.
Pfizer's Phase 2 study of ponsegromab, targeting GDF-15 in cancer cachexia, met primary endpoint of weight change, showing significant increases in body weight, muscle mass, and quality of life. Results presented at ESMO 2024 and published in NEJM, with plans for late-stage development starting in 2025.
Pfizer's Phase 2 study of ponsegromab met primary endpoint, showing 5.6% mean weight increase at highest dose in cancer cachexia patients; improvements in appetite, cachexia symptoms, physical activity, and muscle mass observed; registration-enabling studies planned for 2025.
Pfizer's Phase 2 study of ponsegromab met primary endpoint, showing significant body weight increases compared to placebo across all doses, with a 5.61% mean increase at the highest dose after 12 weeks. Ponsegromab was generally safe and well-tolerated, with improvements in appetite, cachexia symptoms, physical activity, and muscle mass at the highest dose. Pfizer plans to initiate registration-enabling studies in 2025.
Pfizer’s Phase II study of ponsegromab showed significant weight and muscle function improvements in cancer cachexia patients. The 12-week treatment with ponsegromab (400 mg) led to a 5.61% weight gain and better appetite, physical activity, and overall symptoms. No clinically significant adverse events were reported. Pfizer plans to initiate registration-enabling studies in 2025.
Pfizer's Phase 2 study of ponsegromab met primary endpoint of body weight increase, with 5.6% mean increase at highest dose, and showed improvements in appetite, cachexia symptoms, physical activity, and muscle mass. Ponsegromab was safe and well-tolerated. Registration-enabling studies planned for 2025.
Investigational GDF-15 inhibitor ponsegromab significantly increased body weight and improved appetite, cachexia symptoms, physical activity, and skeletal muscle mass in cancer cachexia patients, according to a phase II study presented at ESMO.